Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Case 2-2012: a 57-year-old woman with post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation for primary myelofibrosis.
Kost'ál M, Zák P, Vejrazková E, Cermanová M, Belohlávková P, Zavrelová A, Vrbacký F, Rozkos T, Nová M. Kost'ál M, et al. Among authors: belohlavkova p. Acta Medica (Hradec Kralove). 2012;55(3):142-5. doi: 10.14712/18059694.2015.53. Acta Medica (Hradec Kralove). 2012. PMID: 23297524 Free article. No abstract available.
No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia.
Racil Z, Razga F, Klamova H, Voglova J, Belohlavkova P, Malaskova L, Potesil D, Muzik J, Zackova D, Polakova KM, Zdrahal Z, Malakova J, Suttnar J, Dyr J, Mayer J. Racil Z, et al. Among authors: belohlavkova p. Hematol Oncol. 2014 Jun;32(2):87-93. doi: 10.1002/hon.2091. Epub 2013 Aug 20. Hematol Oncol. 2014. PMID: 23963760
Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment.
Jaruskova M, Curik N, Hercog R, Polivkova V, Motlova E, Benes V, Klamova H, Pecherkova P, Belohlavkova P, Vrbacky F, Machova Polakova K. Jaruskova M, et al. Among authors: belohlavkova p. J Exp Clin Cancer Res. 2017 Apr 18;36(1):55. doi: 10.1186/s13046-017-0523-3. J Exp Clin Cancer Res. 2017. PMID: 28420426 Free PMC article.
Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy.
Racil Z, Koritakova E, Sacha T, Klamova H, Belohlavkova P, Faber E, Rea D, Malaskova L, Prochazkova J, Zackova D, Voglova J, Wącław J, Cetkovsky P, Zak P, Mayer J. Racil Z, et al. Among authors: belohlavkova p. Am J Hematol. 2018 Oct;93(10):E342-E345. doi: 10.1002/ajh.25232. Epub 2018 Aug 31. Am J Hematol. 2018. PMID: 30054949 Free article. No abstract available.
Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients - results from real-life prospective study.
Horňák T, Semerád L, Žáčková D, Weinbergerová B, Šustková Z, Procházková J, Bělohlávková P, Stejskal L, Rohoň P, Faber E, Žák P, Mayer J, Ráčil Z. Horňák T, et al. Among authors: belohlavkova p. Leuk Lymphoma. 2020 Feb;61(2):494-496. doi: 10.1080/10428194.2019.1672054. Epub 2019 Oct 3. Leuk Lymphoma. 2020. PMID: 31580157 No abstract available.
25 results